Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

risk, hypersensitivity reactions including angioedema, and thrombotic thrombocytopenic purpura. For full details of adverse reactions and contraindications, see the summary of product characteristics. 3.5 The price of prasugrel is £47.56 per 28-tab pack (excluding VAT, BNF edition 67). The cost of treatment for 12 months is £628.47 (excluding VAT). Costs may vary in different settings because of negotiated procurement discounts. 4 Evidence and interpretation The Appraisal Committee considered evidence submitted by the manufacturer of enzalutamide and a review of this submission by the Evidence Review Group (ERG). 4.1 Clinical effectiveness Prasugrel compared with clopidogrel 4.1.1 The manufacturer and the Assessment Group both identified 1 randomised controlled trial (TRITON-TIMI 38) and 1 publication related to the core clinical cohort from TRITON-TIMI 38 (Wiviott et al. 2011) from a systematic search of the literature. Both the randomised controlled trial and the publication were also considered for the original appraisal of prasugrel (NICE's technology appraisal guidance 182 on prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention). The Assessment Group commented that no new evidence had been identified since the original appraisal was published. 4.1.2 TRITON-TIMI 38 was a randomised double-blind trial that compared prasugrel with clopidogrel in 13,608 patients
